1-20 of 53
Constantine Tam
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study

Free
Constantine Tam, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Jacob Soumerai, Paolo Ghia, Sophie Leitch, David Westerman, Sheel Patel, Yiqian Fang, James Hilger, Remus Vezan, Chan Cheah
Journal: Blood
Blood (2025) 146 (Supplement 1): 3891.
https://doi.org/10.1182/blood-2025-3891
Published: 2025
Journal Articles

Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-101

Free
Jacob Soumerai, Stephen Opat, Chan Cheah, Mazyar Shadman, Emma Verner, Monica Tani, Marc Hoffmann, Lori Leslie, Shuo Ma, Yiqian Fang, Gabriel Man, Binghao Wu, Charity Henrich, Sheel Patel, Remus Vezan, Constantine Tam
Journal: Blood
Blood (2025) 146 (Supplement 1): 3890.
https://doi.org/10.1182/blood-2025-3890
Published: 2025
Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Free
Michael Wang, Jonathon Cohen, Nirav Shah, Wojciech Jurczak, Pier Luigi Zinzani, Chan Cheah, Chaitra Ujjani, Youngil Koh, Won Seog Kim, Sunita Dwivedy Nasta, Ian Flinn, Benoit Tessoulin, Shuo Ma, Alvaro Alencar, David Lewis, Jennifer Woyach, Kami Maddocks, Krish Patel, Yucai Wang, Joanna Rhodes, Constantine Tam, John Seymour, Hirokazu Nagai, Julie Vose, Bita Fakhri, Marc Hoffmann, Francisco Hernandez-Ilizaliturri, Andrew Zelenetz, Anita Kumar, Talha Munir, Donald Tsai, Paolo Abada, Minna Balbas, Jian Li, Ying (denise) Wang, Lindsey Roeker, Toby Eyre
Journal: Blood
Blood (2025) 146 (Supplement 1): 665.
https://doi.org/10.1182/blood-2025-665
Published: 2025
Journal Articles

A simple scoring system for response and toxicity following lymphoma CAR-T: Results from the Australian CAR-T real-world consortium

Free
Mark Dowling, Vinay Vanguru, Stephen Boyle, Catelyn Cashion, Shafqat Inam, Thomas Buss, Anthony Jeffrey, Hamish Scott, Ross MacDonald, Jian Li, Nicole O'Leary, Adrian Minson, Christina Brown, Mary Ann Anderson, Gaurav Sutrave, Safia Belbachir, Jason Butler, Cameron Curley, Allison Barraclough, Constantine Tam, Andrea Henden, Emily Blyth, Phoebe Joy Ho, Simon Harrison, Michael Dickinson
Journal: Blood
Blood (2025) 146 (Supplement 1): 399.
https://doi.org/10.1182/blood-2025-399
Published: 2025
Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

Free
Romain Guieze, Annamaria Frustaci, Chan Cheah, John Seymour, Dok Hyun Yoon, Irina Mocanu, Eric Mou, Pier Luigi Zinzani, Amitkumar Mehta, Constantine Tam, Judith Trotman, Yanan Zhang, Linlin Xu, Kunthel By, Amber Lussier, Shannon Fabre, Daniel Persky, Ranjana Advani
Journal: Blood
Blood (2025) 146 (Supplement 1): 3584.
https://doi.org/10.1182/blood-2025-3584
Published: 2025
Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

Free
Constantine Tam, Chan Cheah, John Seymour, Ricardo Parrondo, Mazyar Shadman, Damien Roos Weil, Stephan Stilgenbauer, Barbara Eichhorst, Herbert Eradat, Steven Treon, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Motohisa Takai, Amit Agarwal, Annamaria Frustaci
Journal: Blood
Blood (2025) 146 (Supplement 1): 3583.
https://doi.org/10.1182/blood-2025-3583
Published: 2025
Journal Articles

MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101

Free
Marc Hoffmann, Shuo Ma, Herbert Eradat, Constantine Tam, Masa Lasica, Paul Hampel, Emma Verner, Lori Leslie, Christopher D'Angelo, Jacob Soumerai, Mazyar Shadman, Chan Cheah, Monica Tani, Yiqian Fang, Binghao Wu, Gabriel Man, Sheel Patel, Remus Vezan, Stephen Opat
Journal: Blood
Blood (2025) 146 (Supplement 1): 793.
https://doi.org/10.1182/blood-2025-793
Published: 2025
Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Free
Chan Cheah, Manish Patel, Toby Eyre, Wojciech Jurczak, David Lewis, Thomas Gastinne, Shuo Ma, Jonathon Cohen, Krish Patel, Jennifer Brown, Lydia Scarfo, Talha Munir, Ewa Lech-Maranda, Marc Hoffmann, Chaitra Ujjani, Bita Fakhri, Michael Wang, Koji Izutsu, Hirokazu Nagai, Constantine Tam, Joanna Rhodes, Julie Vose, Matthew McKinney, James Gerson, Minal Barve, Bryone Kuss, Youngil Koh, Aisling Barrett, Steven Treon, Jorge Castillo, John Seymour, Amy Ruppert Stark, Samuel McNeely, Richard Walgren, Donald Tsai, Katherine Bao, Binoj Chandrasekharan Nair, Jennifer Woyach, Lia Palomba
Journal: Blood
Blood (2025) 146 (Supplement 1): 226.
https://doi.org/10.1182/blood-2025-226
Published: 2025
Journal Articles

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

Free
Constantine Tam, Talha Munir, Tadeusz Robak, Jennifer Brown, Brad Kahl, Paolo Ghia, Stephen Opat, Patricia Walker, Masa Lasica, Ian Flinn, Jiayi Shen, Nataliya Kuptsova-Clarkson, Marcus Lefebure, Jamie Hirata, Wojciech Jurczak, Mazyar Shadman
Journal: Blood
Blood (2025) 146 (Supplement 1): 2129.
https://doi.org/10.1182/blood-2025-2129
Published: 2025
Journal Articles

Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL): Up to 6 years of follow-up with the long-term extension (LTE1)

Free
Constantine Tam, Andrzej Mital, Robert Weinkove, Wojciech Jurczak, Xin Yan, Nataliya Kuptsova-Clarkson, Tian Tian, Megan Wang, Jamie Hirata
Journal: Blood
Blood (2025) 146 (Supplement 1): 2123.
https://doi.org/10.1182/blood-2025-2123
Published: 2025
Journal Articles

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Free
William Wierda, Jennifer Brown, Paolo Ghia, Lindsey Roeker, Krish Patel, Toby Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine Tam, John Seymour, Benoit Tessoulin, Nirav Shah, Chaitra Ujjani, Bita Fakhri, Catherine Coombs, Ian Flinn, Manish Patel, Sunita Dwivedy Nasta, Jonathon Cohen, Alvaro Alencar, Chan Cheah, Shuo Ma, Joanna Rhodes, Deepa Jagadeesh, Pier Luigi Zinzani, Anders Österborg, Koji Izutsu, Noriko Fukuhara, Donald Tsai, Paolo Abada, Minna Balbas, Jian Li, Ying (denise) Wang, Wojciech Jurczak, Jennifer Woyach
Journal: Blood
Blood (2025) 146 (Supplement 1): 2115.
https://doi.org/10.1182/blood-2025-2115
Published: 2025
Journal Articles

Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Results from the ALPINE trial

Free
Jennifer Brown, Timothy Victor, Alan Wu, Nicole Lamanna, Constantine Tam, Lugui Qiu, Rasika Korde, Tommi Salmi, Gisoo Barnes, Mazyar Shadman
Journal: Blood
Blood (2025) 146 (Supplement 1): 711.
https://doi.org/10.1182/blood-2025-711
Published: 2025
Journal Articles

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor

Free
Constantine Tam, John Seymour, Jiayi Shen, Jan Michel, Maryam Sarraf Yazdy, Patrick Brown, Shelonitda Rose, Motohisa Takai, Meghan Thompson, Mark-David Levin, Talha Munir, Paolo Ghia, Jeff Sharman
Journal: Blood
Blood (2025) 146 (Supplement 1): 8245.
https://doi.org/10.1182/blood-2025-8245
Published: 2025
Journal Articles

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Free
Jing-Zhou Hou, Tae Min Kim, Seok-Goo Cho, Sameh Gaballa, Ranjit Nair, Koji Izutsu, Sumana Devata, Dok Hyun Yoon, Won-Seog Kim, Yazeed Sawalha, Ryan Jacobs, Eliza Hawkes, Ming-Chung Wang, Constantine Tam, Don Stevens, Hisayuki Yokoyama, Jin Seok Kim, Matthew Matasar, Aravind Ramakrishnan, Denise Brennan, David Sermer, Robin Lesley, Mihail Obrocea, Dai Maruyama
Journal: Blood
Blood (2025) 146 (Supplement 1): 1005.
https://doi.org/10.1182/blood-2025-1005
Published: 2025
Journal Articles

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Free
Tae Min Kim, Jing-Zhou Hou, Sameh Gaballa, Ranjit Nair, Dai Maruyama, Koji Izutsu, Sumana Devata, Dok Hyun Yoon, Won-Seog Kim, Yazeed Sawalha, Ryan Jacobs, Eliza Hawkes, Ming-Chung Wang, Constantine Tam, Don Stevens, Hisayuki Yokoyama, Jin Seok Kim, Matthew Matasar, Aravind Ramakrishnan, Denise Brennan, David Sermer, Robin Lesley, Xu (Sue) Zhu, Mihail Obrocea, Seok-Goo Cho
Journal: Blood
Blood (2025) 146 (Supplement 1): 5514.
https://doi.org/10.1182/blood-2025-5514
Published: 2025
Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study

Free
Inhye Ahn, Ricardo Parrondo, Meghan Thompson, Annamaria Frustaci, John Allan, Paolo Ghia, Irina Mocanu, Damien Roos Weil, Constantine Tam, Stephan Stilgenbauer, Judith Trotman, Lydia Scarfo, Nicole Lamanna, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Daniel Persky, Amit Agarwal, John Seymour
Journal: Blood
Blood (2025) 146 (Supplement 1): 85.
https://doi.org/10.1182/blood-2025-85
Published: 2025
Journal Articles

Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States

Free
Jennifer Brown, Swetha Challagulla, David Campbell, Qianhong Fu, Wassim Aldairy, Keri Yang, Rhys Williams, Constantine Tam
Journal: Blood
Blood (2025) 146 (Supplement 1): 7443.
https://doi.org/10.1182/blood-2025-7443
Published: 2025
Journal Articles

CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Free
Meghan Thompson, Constantine Tam, Kenneth Wu, Sheel Patel, Motohisa Takai, Patrick Phuong, Shelonitda Rose, Mark-David Levin, Talha Munir, Paolo Ghia, John Seymour
Journal: Blood
Blood (2025) 146 (Supplement 1): 5691.
https://doi.org/10.1182/blood-2025-5691
Published: 2025
Journal Articles

Real-world outcomes with CAR T-cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement

Free
Catelyn Cashion, Jian Li, Sergio Farina, Shafqat Inam, Anthony Jeffrey, Ross MacDonald, Thomas Buss, Vinay Vanguru, Stephen Boyle, David Bishop, Christina Brown, Allison Barraclough, Constantine Tam, Andrea Henden, Michael Dickinson, Emily Blyth, Mark Dowling
Journal: Blood
Blood (2025) 146 (Supplement 1): 1936.
https://doi.org/10.1182/blood-2025-1936
Published: 2025
Journal Articles

Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.

Free
Jian Li, Mark Dowling, Anthony Jeffrey, Sergio Farina, Stephen Boyle, Ross MacDonald, Shafqat Inam, Chun Kei Kris Ma, Vinay Vanguru, Nilu Perera, Hamish Scott, Michael Dickinson, John Seymour, Andrea Henden, Emily Blyth, Phoebe Joy Ho, Constantine Tam, Mary Ann Anderson, Philip Thompson
Journal: Blood
Blood (2025) 146 (Supplement 1): 2779.
https://doi.org/10.1182/blood-2025-2779
Published: 2025